{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-026760","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2022-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.891705+00:00","generated_at":"2026-06-21T02:37:18.437466+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arcus ARC-7 Phase 2: domvanalimab doublet cuts progression risk 45% vs. zimberelimab","bullets":["Median PFS: doublet 12.0 mo, triplet 10.9 mo vs. monotherapy 5.4 mo (HR 0.55 and 0.65).","Confirmed ORR: doublet 41%, triplet 40% vs. monotherapy 27% in PD-L1≥50% 1L NSCLC.","Six-month PFS rate: doublet 65%, triplet 63% vs. monotherapy 43%; median follow-up ~12 mo.","No new safety signals; Grade≥3 AEs: doublet 47%, triplet 52% vs. monotherapy 58%.","Trial continues to monitor overall survival; data cutoff Aug 31, 2022 (n=149 safety, 133 efficacy)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-026760","json":"https://secwatch.observer/filing/0000950170-22-026760.json","markdown":"https://secwatch.observer/filing/0000950170-22-026760.md","text":"https://secwatch.observer/filing/0000950170-22-026760.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000095017022026760/0000950170-22-026760-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000095017022026760/rcus-20221219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T02:37:18.437466+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}